Want to see PYXS full AI Analyst Report?

Pyxis Oncology (PYXS) Price & Analysis

636 Followers

PYXS Stock Chart & Stats

$1.66

-$0.10(-5.75%)

At close: Jan 08 4:00 PM EST

$1.66

-$0.10(-5.75%)

Day’s Range― - ―

52-Week Range$0.97 - $5.55

Previous CloseN/A

Volume258.73K

Average Volume (3M)757.02K

Market Cap

$149.52M

Enterprise Value$68.43

Total Cash (Recent Filing)$42.49M

Total Debt (Recent Filing)$18.26M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Aug 19, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.31

Shares Outstanding63,355,480

10 Day Avg. Volume789,983

30 Day Avg. Volume757,017

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)1.34

Price to Sales (P/S)5.16

P/FCF Ratio-1.13

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$6.50

Price Target Upside291.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.21

Revenue Forecast (FY)$58.33K

Bulls Say, Bears Say

Bulls Say

Extended Cash Runway Via FinancingThe June 2026 private placement materially strengthens near-term liquidity and extends runway into Q2 2027, reducing immediate funding pressure. This gives management time to advance MICVO trials, generate clinical readouts, and de-risk programs before needing dilutive financing.

Focused Immuno‑Oncology PipelinePyxis’s concentrated strategy on monoclonal antibodies and ADCs in immuno-oncology aligns with durable industry demand for targeted biologics. Specialization across modalities increases strategic optionality and potential for high-margin products if clinical programs translate to approvals.

Governance And Oversight StabilityBoard continuity from elected directors and appointment of a reputable audit firm strengthen governance and financial oversight. Robust oversight supports disciplined clinical development, regulatory compliance, and credible investor communications over the medium term.

Bears Say

Persistent High Cash BurnSustained ~-$67M annual cash outflow reflects ongoing R&D and operating costs that will require repeated capital raises absent commercialization. This persistent burn increases dilution risk and constrains investments in multiple programs, pressuring long-term financial flexibility.

Deep And Ongoing Operating LossesLarge, sustained losses signal the company is far from revenue-positive operations; negative margins limit internal funding for trials and commercialization. Continued unprofitability increases dependency on external capital and heightens risk if clinical milestones are delayed or unsuccessful.

Eroded Equity CushionA sharply reduced equity base and shrinking total assets weaken the balance-sheet buffer against setbacks. Even with moderate headline debt, limited equity reduces capacity to absorb trial failures or pursue opportunistic investments without materially dilutive financing.

Pyxis Oncology News

Pyxis Oncology announces up to $114M private placement

Pyxis Oncology (PYXS) announced that it has entered into definitive securities purchase agreements for a private placement expected...

21d ago

PYXS

Pyxis Oncology Raises Capital Through Private Placement Financing

The latest announcement is out from Pyxis Oncology ( ($PYXS) ). Pyxis Oncology entered into definitive securities purchase...

18d ago

PYXS

Pyxis Oncology Stockholders Approve Directors and Auditor Slate

Pyxis Oncology ( ($PYXS) ) has shared an announcement. On June 15, 2026, Pyxis Oncology, Inc. held its...

1M ago

PYXS

Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility

Pyxis Oncology, Inc. (PYXS) has disclosed a new risk, in the Debt & Financing category. Pyxis Oncology, Inc....

2M ago

PYXS

Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)

“Our team’s exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm...

2M ago

PYXS

PYXS Earnings this Week: How Will it Perform?

Pyxis Oncology, Inc. (PYXS) is scheduled to report 1st quarter earnings on 05/08/2026. Regarding Q1 estimates, Wall Street...

3M ago

PYXS

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

As previously reported, Wedbush analyst Robert Driscoll initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and...

3M ago

PYXS

Pyxis Oncology initiated with an Outperform at Wedbush

Wedbush initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and $6 price target Published first on...

3M ago

PYXS

Pyxis Oncology price target lowered to $8 from $9 at Stifel

Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $8 from $9 and keeps a Buy...

4M ago

PYXS

Pyxis Oncology Reports Q4 Results, Advances MICVO Program

The latest announcement is out from Pyxis Oncology ( ($PYXS) ). Pyxis Oncology reported a series of clinical...

4M ago

PYXS

PYXS Earnings this Week: How Will it Perform?

Pyxis Oncology, Inc. (PYXS) is scheduled to report 4th quarter earnings on 03/25/2026. Regarding Q4 estimates, Wall Street...

4M ago

PYXS

Pyxis Oncology Announces Interim CEO Amid Leadership Transition

Pyxis Oncology ( ($PYXS) ) has shared an update. On February 2, 2026, Pyxis Oncology implemented a leadership...

5M ago

PYXS

Pyxis Oncology appoints board member Thomas Civik as Interim CEO

Pyxis Oncology (PYXS) announced a leadership transition. Thomas Civik, a member of Pyxis Oncology’s Board of Directors since...

6M ago

PYXS

3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts

Looking for top-rated stocks to buy now? Recent analyst updates highlight three biotech companies that have earned Strong...

7M ago

PYXS

RGNX

PYXS FAQ

What was Pyxis Oncology’s price range in the past 12 months?

Pyxis Oncology lowest stock price was $0.97 and its highest was $5.55 in the past 12 months.

What is Pyxis Oncology’s market cap?

Pyxis Oncology’s market cap is $149.52M.

When is Pyxis Oncology’s upcoming earnings report date?

Pyxis Oncology’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.

How were Pyxis Oncology’s earnings last quarter?

Pyxis Oncology released its earnings results on May 14, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.364 by -$0.006.

Is Pyxis Oncology overvalued?

According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pyxis Oncology pay dividends?

Pyxis Oncology does not currently pay dividends.

What is Pyxis Oncology’s EPS estimate?

Pyxis Oncology’s EPS estimate is -0.34.

How many shares outstanding does Pyxis Oncology have?

Pyxis Oncology has 63,355,480 shares outstanding.

What happened to Pyxis Oncology’s price movement after its last earnings report?

Pyxis Oncology reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.364. Following the earnings report the stock price went down -15.649%.

Which hedge fund is a major shareholder of Pyxis Oncology?

Currently, no hedge funds are holding shares in PYXS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pyxis Oncology Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-52.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pyxis Oncology

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Pyxis Oncology (PYXS) Earnings & Revenues

Historic Earnings Reports

PYXS Stock 12 Month Forecast

Average Price Target

$6.50

▲(291.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,3.246153846153846,3.6423076923076927,4.038461538461538,4.434615384615385,4.830769230769231,5.226923076923077,5.6230769230769235,6.01923076923077,6.415384615384616,6.811538461538461,7.207692307692309,7.603846153846154,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,3.1307692307692307,3.411538461538462,3.6923076923076925,3.973076923076923,4.253846153846154,4.5346153846153845,4.815384615384616,5.096153846153847,5.376923076923077,5.657692307692308,5.938461538461539,6.219230769230769,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,3.0153846153846153,3.180769230769231,3.3461538461538463,3.5115384615384615,3.676923076923077,3.8423076923076924,4.007692307692308,4.173076923076923,4.338461538461539,4.503846153846154,4.6692307692307695,4.834615384615384,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >